Clostridioides difficile infection is challenging to diagnose and treat and is associated with considerable mortality, morbidity and economic costs worldwide. In this Review, Chilton et al. discuss changes in global epidemiology, breakthroughs in pathogenesis and antibiotic resistance, the role of microbiota dysbiosis and the potential for microbiota-based therapeutics for Clostridioides difficile infection.
- Caroline H. Chilton
- Virginie Viprey
- Mark H. Wilcox
